Results of drug trials must be open to public scrutiny

September 09, 2004

The results of all clinical trials - for new drugs and procedures - must be released publicly if people are to get the full facts about their medical treatment, says a letter in this week's BMJ.

Writing from Japan Professor Furukawa, a specialist in psychiatry, argues that if detailed results of trials are not published openly, the public and health professionals are forced to rely on the drug company involved to interpret the trial findings - an interpretation which may not reflect the results fully, says the author.

Examining the trial results of a drug for treating depression in children, Professor Furukawa argues that the drug company has mislabled some of the results, and wrongly categorized others. A child with symptoms of hopelessness and suicidal thoughts, who "punched pictures, broke glass and sustained lacerations that required six sutures", was categorized as a case of aggression, says Professor Furukawa - rather than the more serious diagnosis of emotional liability or suicidal tendencies. Without access to the data itself, a doctor or parent is not in a position to challenge the drug company's findings.

All clinical trials results - not just those from drug companies - should be publicly accessible and reported in detail, argues the author. If such a policy were adopted internationally, healthcare professionals and the public could at last make properly informed decisions.
-end-


BMJ

Related Clinical Trials Articles from Brightsurf:

Nearly 1 in 5 cancer patients less likely to enroll in clinical trials during pandemic
A significant portion of cancer patients may be less likely to enroll in a clinical trial due to the ongoing coronavirus pandemic.

COVID-19 clinical trials lack diversity
Despite disproportionately higher rates of COVID-19 infection, hospitalization and death among people of color, minority groups are significantly underrepresented in COVID-19 clinical trials.

Why we should trust registered clinical trials
In a time when we have to rely on clinical trials for COVID-19 drugs and vaccines, a new study brings good news about the credibility of registered clinical trials.

Inclusion of children in clinical trials of treatments for COVID-19
This Viewpoint discusses the exclusion of children from coronavirus disease 2019 (COVID-19) clinical trials and why that could harm treatment options for children.

Review evaluates how AI could boost the success of clinical trials
In a review publishing July 17, 2019 in the journal Trends in Pharmacological Sciences, researchers examined how artificial intelligence (AI) could affect drug development in the coming decade.

Kidney patients are neglected in clinical trials
The exclusion of patients with kidney diseases from clinical trials remains an unsolved problem that hinders optimal care of these patients.

Clinical trials beginning for possible preeclampsia treatment
For over 20 years, a team of researchers at Lund University has worked on developing a drug against preeclampsia -- a serious disorder which annually affects around 9 million pregnant women worldwide and is one of the main causes of death in both mothers and unborn babies.

Underenrollment in clinical trials: Patients not the problem
The authors of the study published this month in the Journal of Clinical Oncology investigated why many cancer clinical trials fail to enroll enough patients.

When designing clinical trials for huntington's disease, first ask the experts
Progress in understanding the genetic mutation responsible for Huntington's disease (HD) and at least some molecular underpinnings of the disease has resulted in a new era of clinical testing of potential treatments.

New ALS therapy in clinical trials
New research led by Washington University School of Medicine in St.

Read More: Clinical Trials News and Clinical Trials Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.